Literature DB >> 3839000

Changes in calcium homeostasis in acromegaly treated by pituitary adenomectomy.

S Takamoto, H Tsuchiya, T Onishi, S Morimoto, S Imanaka, S Mori, Y Seino, T Uozumi, Y Kumahara.   

Abstract

Patients with acromegaly have alterations in mineral metabolism. To determine the effect of correction of excess GH secretion on calcium metabolism, we studied 12 acromegalic patients before and 3-4 weeks after pituitary adenomectomy. Treatment of acromegaly resulted in significant decreases in both serum calcium [from 9.3 +/- 0.2 to 8.7 +/- 0.1 mg/dl (mean +/- SEM); P less than 0.01] and urinary calcium excretion (from 200 +/- 24 to 88 +/- 12 mg/24 h; P less than 0.0002). Serum phosphate also decreased significantly (P less than 0.01) from 4.8 +/- 0.2 to 4.3 +/- 0.2 mg/dl. Both serum immunoreactive PTH and calcitonin levels were normal initially and did not change after surgery. The mean serum 25-hydroxyvitamin D (25OHD) level was significantly (P less than 0.01) lower and the 1,25-dihydroxyvitamin D [1,25-(OH)2D] level was significantly (P less than 0.0001) higher in acromegaly compared with measurements in 25 normal subjects. After surgery, the serum 25OHD level did not change; however, the serum 1,25-(OH)2D concentration fell significantly (P less than 0.0001) from 60 +/- 4 to 43 +/- 2 pg/ml. A positive correlation was found between the decrements in urinary calcium excretion and the serum 1,25-(OH)2D level when the comparison was made between the decrements as percentages of pretreatment values (r = 0.64; P less than 0.05). The accumulated data suggest that the hypercalciuria in acromegaly might be due to intestinal calcium hyperabsorption, which could be attributed to the elevated circulating 1,25-(OH)2D level. Excessive GH secretion might stimulate the production of 1,25-(OH)2D and might also directly stimulate calcium absorption.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 3839000     DOI: 10.1210/jcem-61-1-7

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN: 0021-972X            Impact factor:   5.958


  14 in total

Review 1.  Acromegaly as a cause of 1,25-dihydroxyvitamin D-dependent hypercalcemia: case reports and review of the literature.

Authors:  Reshma Shah; Angelo Licata; Nelson M Oyesiku; Adriana G Ioachimescu
Journal:  Pituitary       Date:  2012-12       Impact factor: 4.107

2.  Effect of growth hormone on urine calcium and serum vitamin D metabolites in renal failure.

Authors:  C F Strife; G Hug
Journal:  Pediatr Nephrol       Date:  1996-10       Impact factor: 3.714

3.  Utility of baseline serum phosphorus levels for predicting remission in acromegaly patients.

Authors:  G Y Yalin; S Tanrikulu; N Gul; A K Uzum; F Aral; R Tanakol
Journal:  J Endocrinol Invest       Date:  2017-03-29       Impact factor: 4.256

4.  Characterization of vitamin D metabolism in active acromegaly in the setting of bolus (150,000 IU) cholecalciferol treatment.

Authors:  Alexandra A Povaliaeva; Viktor P Bogdanov; Artem Yu Zhukov; Ekaterina A Pigarova; Larisa K Dzeranova; Liudmila Ya Rozhinskaya; Galina A Mel'nichenko; Natalia G Mokrysheva
Journal:  Endocrine       Date:  2022-02-09       Impact factor: 3.633

5.  Long-term effects of octreotide on markers of bone metabolism in acromegaly: evidence of increased serum parathormone concentrations.

Authors:  P Legovini; E De Menis; F Breda; D Billeci; A Carteri; P Pavan; N Conte
Journal:  J Endocrinol Invest       Date:  1997-09       Impact factor: 4.256

Review 6.  Growth hormone, insulin-like growth factors, and the skeleton.

Authors:  Andrea Giustina; Gherardo Mazziotti; Ernesto Canalis
Journal:  Endocr Rev       Date:  2008-04-24       Impact factor: 19.871

Review 7.  How safe is the treatment of uraemic children with recombinant human growth hormone?

Authors:  B Tönshoff; U Heinrich; O Mehls
Journal:  Pediatr Nephrol       Date:  1991-07       Impact factor: 3.714

8.  Vitamin D-binding protein and free vitamin D concentrations in acromegaly.

Authors:  Alev Eroglu Altinova; Cigdem Ozkan; Mujde Akturk; Ozlem Gulbahar; Muhittin Yalcin; Nuri Cakir; Fusun Balos Toruner
Journal:  Endocrine       Date:  2015-11-07       Impact factor: 3.633

9.  Investigation of the vitamin D receptor polymorphisms in acromegaly patients.

Authors:  Muzaffer Ilhan; Bahar Toptas-Hekimoglu; Ilhan Yaylim; Seda Turgut; Saime Turan; Ozcan Karaman; Ertugrul Tasan
Journal:  Biomed Res Int       Date:  2015-03-08       Impact factor: 3.411

10.  Vanishing hypercalciuric kidney stones after treating underlying acromegaly.

Authors:  Eline van der Valk; Tom Tobe; Aline Stades; Alex Muller
Journal:  Endocrinol Diabetes Metab Case Rep       Date:  2013-07-01
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.